elev8.vc

Good signs for deep-tech startups in Singapore and in SEA!

Our MD, Aditya Mathur recently spoke with The Business Times about the growth of deep tech in Singapore's ecosystem. We are seeing a disproportionate percentage of capital flowing into deep-tech. This is great news for our eco-system! According to Singapore's sovereign deep-tech investor SEEDS Capital, Singapore accounted for about three-quarters of the total deep-tech deal volume in South-east Asia in the first nine months of 2023. We couldn't be more proud to be a part of this ecosystem! Great article Daphne Yow Read more here: https://bt.sg/S3vV

Today’s my 4th anniversary at elev8.vc! Here’s what I learnt from 7 years in #deeptech - 3 in public service and 4 in private sector. This will be a 3 part series: 1. Lessons in VC 2. Lessons founders taught me 3. Lessons from the ecosystem Here we go. Part 1 of 3 - Lessons in Early Stage Deep Tech VC 1. It’s extreme hard work ☠️. Founders trust me with their dreams; LPs trust me with their cash; my greatest fear is failing them because I was lazy. Jason Calacanis said in a recent podcast he hires “hungry” fresh grads to work 50-60 hours a week. I’m disturbed by how little that is. 😮💨 2. 📈Value creation is much harder than I could have imagined. Probably why so few actually do it. 4 years ago I set out to create a “value accretive due diligence” process. We were probably the first VC that did it. It would be great to see more investors adopt a value creation mindset. 3. Most of what we learnt about VC is wrong ❌. Because most of VC literature focuses on the valley during the internet and mobile eras. APAC and deep tech is entirely different. Just because Facebook, Amazon, or TikTok was built that way doesn’t mean it’s The Way. 🇸🇬 is not 🇺🇸 4. Startups are incredibly complex. There’s no single point of success or failure. Any startup evaluation needs to consider dozens/hundreds of parameters AND their interdependencies. I used to think a super process means super results - can’t be more wrong. 5. To level up local deep tech investors we need original, visionary thinkers. We need people who see the future and the possibilities. I’m still waiting for someone to tell me Apple’s Vision Pro looks like it could be an MVP for the Apple Car 🚙; instead of mocking how a $5k consumer device will fail because COGS, CAC, or some 🧐 academic metric. 6. Ikigai or nothing! Being a good early stage VC is so important and so hard that it needs to be your purpose and meaning. Don’t mess with founders’ and LPs’ trust if you’re not 💯% in it. I’ll try to post all 3 parts today so stay tuned for part 2 on the lessons I learnt from founders!

We are happy to share Vogue editorial published today announcing COzTERRA as one of the 3 finalists of the Vogue x BMW Group Innovation Prize 2023. COzTERRA is the brand created by Xinterra for its CO2 removal materials, starting with textiles. The winner will be announced on Nov 18th. Stay tuned!

We were honoured to meet and share our vision on the future of space exploration and propulsion with Deputy Prime Minister, Mr Heng Swee Keat at the SWITCH Exhibition in Singapore. Do visit our booth at the Marina Bay Sands to learn more!

Mesh Bio announces Regulatory Approval for HealthVector® Diabetes for prediction of Chronic Kidney Disease in Type 2 Diabetes patients & I2Adopt Grant with SGH and TTSH for clinical adoption Mesh Bio is thrilled to announce two significant milestones. First, our HealthVector® Diabetes, is the world’s first digital twin technology to obtain regulatory approval for clinical use as a Software as a Medical Device (SaMD) from the Health Sciences Authority (HSA). Secondly, HealthVector® Diabetes has been selected for an implementation pilot at Singapore General Hospital (SGH), Tan Tock Seng Hospital (TTSH), and selected polyclinics for potential clinical adoption. The implementation pilot is supported by the National Health Innovation Centre (NHIC), through the Innovation to Adopt (I2Adopt) Grant. HealthVector® Diabetes, powered by cutting-edge computational systems biology and AI, predicts the 3-year onset risk of Chronic Kidney Disease (CKD) in type 2 diabetes patients. By analyzing anonymized clinical data from electronic medical records, it derives a risk score for prediction of worsened kidney function. This has the potential to transform the care of patients, as clinicians can use this information to prioritise and intensify therapeutics to delay the progression of kidney failure. With approximately 1 in 12 Singapore residents affected by diabetes, and about 40% of them at risk of developing CKD, the need for personalized care is evident. Unmanaged CKD could cost an estimated S$300 million annually. This highlights the need for solutions like HealthVector Diabetes, which will enable patient risk stratification for CKD so that care can be personalised for better outcomes. We're excited about the future of healthcare, focusing on prevention and personalized care. Mesh Bio is dedicated to driving innovation and improving patient outcomes. Read more on it in the link below! https://lnkd.in/gkmenNeJ Dr Andrew Wu, Arsen Batagov, Naveenah Udaya Surian, Dr Wen Bin, Dr Rinkoo Dalan, Dr Yong Mong B.

Singapore has become a premier destination for innovation, especially in deep-tech. Our MD, Aditya Mathur, shares his notes on the some of the reasons. Thank you Bloomberg and Enterprise Singapore for this excellent article. Great intro to some our portfolio companies: Polybee Moon Technologies Mesh Bio https://lnkd.in/gqtGwuNy

Catch our MD, Aditya Mathur, as he speaks about the state of health tech in SEA with an incredible panel. Thank you MRANTI and Tuan Nguyen for organising.

Getting ready to talk about our favourite subject: deep-tech investing in Singapore. Behind the scenes courtesy of some of our favourite partners. More to come... elev8.vc x SEEDS Capital x Curium #deeptech #Singapore #impactinvestors cc Remi Choong, Aditya Mathur